STAT+: Pharmalittle: We’re reading about a U.S. vaccine panel, an abortion pill, and much more
And so, another working week will soon draw to a close. Not a moment too…
Category: Pharma
Gilead sours on the ‘don’t eat me’ business
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: As Medicare drug pricing negotiations begin, AstraZeneca stays mum on government’s offer
LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor…
STAT+: Years into an addiction crisis, a med school lecture still minimized opioid risks
Amid ongoing concern over opioid addiction, a university in Florida has been criticized for allowing…
The GLP-1 panic is alive and well
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about worries over a Novo deal, a PBM bill, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: AI can speed up drug discovery but don’t expect it to cure cancer, yet
David Reese calls it a “hinge moment” — the turning point when biotech and big…
STAT+: Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
The Colombian government has taken a significant step toward issuing a compulsory license for a…
Opinion: Aduhelm was a mess — and it could happen again
Last week, Biogen announced it will cease both the study and sale of Aduhelm, its…
Vertex still knows how to do what it does best
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: A sweeping new lawsuit asks: Are employers liable if they overpay for drugs?
Johnson & Johnson faces a consequential new class action lawsuit — not in its role…
.jpg)
STAT+: Diabetes treatments have improperly listed patents that should be removed, analysis finds
More than half of the injector-pen patents for several widely used diabetes treatments — including…
Regeneron is interested in obesity treatments that combat muscle loss
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production
LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent…
Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down
Amgen is trying a unique strategy with its obesity drug candidate: testing whether it can…
STAT+: Pharmalittle: We’re reading about opioid settlements, an OTC birth control pill, and more
And so, another working week will soon draw to a close. Not a moment too…
What makes a drug a blockbuster — or a cautionary tale?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novavax is on thin ice, and the latest update isn’t exactly encouraging
Want to stay on top of the science and politics driving biotech today? Sign up to…
STAT+: Pharmalittle: We’re reading about Medicare price negotiations, slowing layoffs, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Judge skeptical of arguments against Medicare drug price negotiation
WILMINGTON, Del. — Today was the first time that a federal judge asked questions in-person…
STAT+: WTO appears close to rejecting a proposed waiver on patents for Covid diagnostics and therapies
After more than a year of deliberation, the World Trade Organization appears close to rejecting…
Pfizer’s reset year starts with a little profit
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Experts critique flawed system for monitoring drugs’ side effects in wake of asthma drug report
After a drug enters the market, it’s up to Food and Drug Administration regulators to…
STAT+: As supply crunch starts to ease, Novo Nordisk to offer more doses of obesity drug Wegovy to U.S. patients
LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of…
STAT+: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies
In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell…
How an immunological Trojan horse could treat disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a Vertex pain pill, an abortion pill hearing, and more
Top of the morning to you. And a fine one it is. Despite gray skies,…
STAT+: Can Wegovy treat depression as well as obesity? New research looks to GLP-1 drugs for mental illnesses
Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are…
STAT+: European regulators tout their accomplishments against pharma’s anticompetitive practices
European antitrust regulators want you to know that fighting crime in the pharmaceutical industry pays….
23andMe breach targeted Chinese, Jewish populations
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Pharmalittle: We’re reading about Medicaid and sickle cell, pharma CEOs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Pricey sickle cell treatments raise daunting new challenges for Medicaid programs
Living with sickle cell disease has not been easy on Kourtney Cunningham. The genetic blood…
Eli Lilly overtakes Tesla in market value
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Sanders jabbing Merck’s CEO, fixing drug shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Generic group sues Illinois over a price-gouging law with ‘draconian regulations’
The trade group for generic drug companies in the U.S. has filed a lawsuit alleging…
Merck CEO refused to testify in Senate because he’s not an expert in drug pricing, Bernie Sanders says
WASHINGTON — Sen. Bernie Sanders on Thursday jabbed the CEO of Merck for telling congressional…
STAT+: Key Senate panel considers Medicare bonuses for hospitals that prevent drug shortages
WASHINGTON — A key Senate committee is proposing that Medicare pay bonuses to hospitals that…
Another step toward new drugs for Parkinson’s
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about fake Ozempic, the FTC policing pharma, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: When it comes to policing pharma, the FTC says it’s on ‘an incredible winning streak’
Over the past two years, the U.S. Federal Trade Commission has attempted to crack down…
STAT+: Pharmalittle: We’re reading about Lilly’s gene therapy for hearing, Shkreli’s life-long ban, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Lilly’s gene therapy restores hearing in an 11-year-old, paving way for more treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Ahead of Medicare drug price reform, pharma’s drug pricing has a Streisand effect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about FDA warnings on CAR-T drugs, a Sanofi deal, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Sanofi scoops up U.S. biotech Inhibrx for up to $2.2 billion as it seeks to bolster pipeline
LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday…
STAT+: Pharmalittle: We’re reading about Lilly plant problems, FDA reorganization plans, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…